Susceptibility of human T cell leukemia virus type I to nucleoside reverse transcriptase inhibitors

J Infect Dis. 2003 Aug 1;188(3):424-7. doi: 10.1086/376531. Epub 2003 Jul 10.

Abstract

A single-cycle infection assay with recombinant viral vectors was developed to study human T cell leukemia virus type I (HTLV-I) replication and its inhibition by antiviral agents. The susceptibility of HTLV-I to 6 nucleoside reverse-transcriptase inhibitors was examined. HTLV-I replication was inhibited by tenofovir, abacavir, lamivudine, zalcitabine, stavudine, and zidovudine.

Publication types

  • Comparative Study

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / pharmacology
  • Cell Line
  • Dideoxynucleosides / pharmacology
  • Human T-lymphotropic virus 1 / drug effects*
  • Human T-lymphotropic virus 1 / physiology
  • Humans
  • Lamivudine / pharmacology
  • Microbial Sensitivity Tests
  • Organophosphonates*
  • Organophosphorus Compounds / pharmacology
  • Reverse Transcriptase Inhibitors / pharmacology*
  • Stavudine / pharmacology
  • Tenofovir
  • Virus Replication / drug effects
  • Zalcitabine / pharmacology
  • Zidovudine / pharmacology

Substances

  • Dideoxynucleosides
  • Organophosphonates
  • Organophosphorus Compounds
  • Reverse Transcriptase Inhibitors
  • Lamivudine
  • Zidovudine
  • Zalcitabine
  • Tenofovir
  • Stavudine
  • Adenine
  • abacavir